Japan joins international GMP collaboration

Home/Policies & Legislation | Posted 09/12/2016 post-comment0 Post your comment

The European Medicines Agency (EMA) announced on 25 November 2016 that it would be expanding its ongoing collaboration on good manufacturing practice (GMP) inspections of active pharmaceutical ingredient (API) manufacturers to include Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).

Samsung Bioepis Engineers V16K25LB R

The international collaboration allows manufacturers to share information on inspections of API makers located outside the participating countries. This can include sharing information on planning, as well as policy and reports.

The goal of the collaboration is to increase cooperation and mutual reliance between regulators participating in the initiative, as well as to ensure the best use of inspection resources worldwide.

Other authorities already participating in the collaboration include EU Member States, the European Directorate of the Quality of Medicines and Healthcare (EDQM), the US Food and Drug Administration (FDA), the Australian Therapeutic Goods Administration (TGA), Health Canada and the World Health Organization.

The initiative is in line with EMA’s and the Heads of Medicines Agencies’ strategy to 2020 for the European medicines regulatory framework, which aims to assure product supply chains and the best use of resources as priority areas where the network can make a difference to human and animal health.

Related articles
Joint GMP inspections by EMA and FDA discussed as part of TTIP

EU lists Japan as having equivalent GMP standards

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

Source: EMA

comment icon Comments (0)
Post your comment
Related content
USA BIOSIM Act introduction
02 AA010638
Home/Policies & Legislation Posted 17/09/2021
MERCOSUR: new tariff for biological and biosimilar without Latin equity
138 AA011155
Home/Policies & Legislation Posted 03/09/2021
New trade agreement between Mexico, the US and Canada
62 MD001919
Home/Policies & Legislation Posted 27/08/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010